Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives

BioPharma Dive December 4, 2024
Jonathan Gardner

The company has raised $84 million to advance a so-called GIP antagonist into clinical testing for weight loss.

Antag Therapeutics, a seven-year-old Danish startup investigating a hotly debated approach to treating obesity, has raised 80 million euros, or about $84 million, to advance its first weight loss drug into clinical testing.

Announced Wednesday, the Series A round will support dosing studies of Antag’s lead experimental drug, AT-7687, along with combination trials involving Novo Nordisk’s obesity treatment Wegovy, CEO Alexander Hovard Sparre-Ulrich said in an interview.

Versant Ventures led the round and was joined by Novo Holdings, which provided seed investment, SR One, Pictet, entities associated with KKR and Broadview Ventures, and the Export and Investment Fund of Denmark.

The round...

Today's Sponsors

Today's Sponsor